Skip to main content
. 2022 Jun 3;63(7):100237. doi: 10.1016/j.jlr.2022.100237

Figure 8.

Figure 8

ANGPTL4 ASO reduces plasma lipids in diet-induced obese mice. Male C57BL/6J mice fed a HFD (45 en% fat) were randomly assigned to either treatment with Neg-Ctrl ASO (1.25 mg/kg, n = 10), low-dose ANGPTL4 ASO (0.625 mg/kg, n = 10), or high-dose ANGPTL4 ASO (1.25 mg/kg, n = 10) via subcutaneous injections twice a week for a total duration of 20 weeks. A: Plasma TGs. B: Plasma total TG and VLDL-TG levels as determined by HPLC-based lipoprotein profiling. C: Plasma total cholesterol, LDL-cholesterol, and HDL-cholesterol as determined by HPLC-based lipoprotein profiling. D: Plasma levels of nonesterified fatty acids, glycerol, and glucose. The horizontal bar represents the mean, and the error bars represent SEM. Asterisk indicates significantly different from Neg-Ctrl ASO according to Tukey’s post hoc test. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001.